Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Multiple Sclerosis, Relapsing-Remitting

Known as: Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Remitting-Relapsing 
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial… Expand
National Institutes of Health

Related topics

Related topics

10 relations
GlatiramerIn BloodMicrobiologicalMultiple Sclerosis, Acute Relapsing
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
BACKGROUND Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective… Expand
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
Clinically isolated syndromes (CIS), such as optic neuritis, brainstem or spinal cord syndromes are frequently the first clinical… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
A controlled trial of natalizumab for relapsing multiple sclerosis.
BACKGROUND In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
BACKGROUND Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on… Expand
  • table 1
  • table 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE